Navigation Links
ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
Date:3/14/2010

sk patients with controlled type 2 diabetes mellitus at target for LDL-C. Fenofibrate was chosen because subgroup analyses from previous trials had shown added benefits in patients with type 2 diabetes, or in those with abdominal obesity characteristic of the metabolic syndrome.(10-14) No other clinical trial had previously tested this strategy.

However, the population treated was broader than that recommended by current guidelines for fenofibrate. More than 80 percent of patients did not have sufficiently elevated TG and low HDL-C warranting treatment according to current clinical practice.

ACCORD Lipid established that extending fenofibrate treatment to this broader population did not significantly benefit any of the primary or secondary cardiovascular outcomes in the total study population. However, the study did show a substantial reduction in cardiovascular events with fenofibrate-simvastatin treatment in patients with atherogenic dyslipidemia, with event rates decreasing from 17.3 percent in the simvastatin monotherapy group to 12.4 percent with combination treatment over 4.7 years. This result supports current guidelines and common clinical practice.

More information on the R3i is available from:


'/>"/>
SOURCE Residual Risk Reduction initiative (R3i)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation ... will be presenting at the Baird Healthcare Conference in ... and Chief Financial Officer, will be making a presentation ... EDT on Wednesday, Sept. 3, 2014. A ... the "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... , ... Board: LTUS) ("Lotus" or the "Company") a growing developer ... pharmaceutical,products in the People,s Republic of China ("PRC"), today ... operating entity of Lotus,appointed Mr. Jinzhong HAN to be ...
... ... a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited ... products for pregnant and nursing mothers. , ... Columbia, MD (Vocus) December 10, 2009 -- Martek Biosciences ...
... Collaboration to Create Optimized Antibodies Produces First Candidates Which ... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, ... program between YM and the National Research Council ... IntelliMab(TM) technology, the program is designed to generate novel ...
Cached Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/19/2014)... China,s increasing caesarean section rate, suggests a new commentary ... Journal of Obstetrics and Gynaecology (BJOG) . , China ... the world. Of 16 million babies born in 2010, ... is not known, the current Chinese language literature on ... from 36% to 58%. However, before the 1980s, the ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s not ... the Philippine tarsier: a tiny, adorable and downright "cool" primate ... that Americans are familiar with," said Rafe Brown, curator-in-charge at ... eyes and ears; an extremely cute, furry body; a long ... expanded fingers and toe tips that look a bit like ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... know Edward Teller as the "Father of the H-Bomb." To his ... detractors he was evil personified. Between these extremes was the life ... well researched attempt to interpret the enigmatic nature of a great ... beliefs," says G. A. Keyworth, II, science advisor to President Reagan, ...
... LAFAYETTE, Ind. - Greenhouse plant growers can substitute rice ... for an increase in growth regulators, according to a ... often consists of a soilless mix of peat and ... also regularly use plant-growth regulators to ensure consistent and ...
... Laxenburg, Austria 26th October 2010 --,A new assessment ... warming cautions that unless current imbalances in R&D portfolios ... technologies are redressed, greenhouse gas (GHG) emission reduction targets ... considerable costs. The study identifies energy efficiency as ...
Cached Biology News:'Judging Edward Teller' 2'Judging Edward Teller' 3Rice hulls a sustainable drainage option for greenhouse growers 2Changes in energy R&D needed to combat climate change 2Changes in energy R&D needed to combat climate change 3
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
LAL Chromogenic Endpoint assay...
...
Catch and Release® v2.0 Reversible Immunoprecipitation System...
Biology Products: